Product
Ricover-scheme rituximab
1 clinical trial
1 indication
Indication
Aggressive B-Cell LymphomaClinical trial
Improvement of Outcome and Reduction of Toxicity in Elderly Patients With CD20+ Aggressive B-Cell Lymphoma by an Optimised Schedule of the Monoclonal Antibody Rituximab, Substitution of Conventional by Liposomal Vincristine, and FDG-PET Based Reduction of Therapy in Combination With Vitamin D SubstitutionStatus: Completed, Estimated PCD: 2024-01-18